Received ipilimumab therapy between 03/01/2011 and 6/30/2014

Aged 18 years or older at index date (initiation of ipilimumab)

Diagnosed with melanoma before index

Documented history of an autoimmune disease

Have at least 6 months of continuous pharmaceutical and medical benefit enrollment prior to the index

Have at least 3 months of continuous pharmaceutical and medical benefit enrollment following and including the index date

Study of Autoimmune Disease Complications Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune Diseases